FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030227571> ?p ?o ?g. }

• W2030227571 endingPage "1814" @default.
• W2030227571 startingPage "1807" @default.
• W2030227571 abstract "Many patients with oncogene-driven non-small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression. This study investigated retrospectively the benefits of local ablative therapy (LAT) to central nervous system (CNS) and/or limited systemic disease progression and continuation of crizotinib or erlotinib in patients with metastatic ALK gene rearrangement (ALK+) or EGFR-mutant (EGFR-MT) NSCLC, respectively.Patients with metastatic ALK+ NSCLC treated with crizotinib (n = 38) and EGFR-MT NSCLC treated with erlotinib (n = 27) were identified at a single institution. Initial response to the respective kinase inhibitors, median progression-free survival (PFS1), and site of first progression were recorded. A subset of patients with either nonleptomeningeal CNS and/or four sites or fewer of extra-CNS progression (oligoprogressive disease) suitable for LAT received either radiation or surgery to these sites and continued on the same tyrosine kinase inhibitors. The subsequent median progression-free survival from the time of first progression (PFS2) and pattern of progression were recorded.Median progression-free survival in ALK+ patients on crizotinib was 9.0 months, and 13.8 months for EGFR-MT patients on erlotinib. Twenty-five of 51 patients (49%) who progressed were deemed suitable for local therapy (15 ALK+, 10 EGFR-MT; 24 with radiotherapy, one with surgery) and continuation of the same targeted therapy. Post-LAT, 19 of 25 patients progressed again, with median PFS2 of 6.2 months.Oncogene-addicted NSCLC with CNS and/or limited systemic disease progression (oligoprogressive disease) on relevant targeted therapies is often suitable for LAT and continuation of the targeted agent, and is associated with more than 6 months of additional disease control." @default.
• W2030227571 created "2016-06-24" @default.
• W2030227571 creator A5005886886 @default.
• W2030227571 creator A5012323508 @default.
• W2030227571 creator A5031938359 @default.
• W2030227571 creator A5034705456 @default.
• W2030227571 creator A5044093871 @default.
• W2030227571 creator A5044715236 @default.
• W2030227571 creator A5052885079 @default.
• W2030227571 creator A5052966036 @default.
• W2030227571 creator A5071670695 @default.
• W2030227571 creator A5072767282 @default.
• W2030227571 creator A5082517668 @default.
• W2030227571 date "2012-12-01" @default.
• W2030227571 modified "2023-10-13" @default.
• W2030227571 title "Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer" @default.
• W2030227571 cites W1501842160 @default.
• W2030227571 cites W1534846799 @default.
• W2030227571 cites W1965842207 @default.
• W2030227571 cites W1975559345 @default.
• W2030227571 cites W1979536922 @default.
• W2030227571 cites W1980497534 @default.
• W2030227571 cites W1984654549 @default.
• W2030227571 cites W2002937040 @default.
• W2030227571 cites W2008729597 @default.
• W2030227571 cites W2012103380 @default.
• W2030227571 cites W2020888019 @default.
• W2030227571 cites W2024501410 @default.
• W2030227571 cites W2040317578 @default.
• W2030227571 cites W2060254075 @default.
• W2030227571 cites W2062468238 @default.
• W2030227571 cites W2080648017 @default.
• W2030227571 cites W2085759768 @default.
• W2030227571 cites W2090615329 @default.
• W2030227571 cites W2091755109 @default.
• W2030227571 cites W2096156234 @default.
• W2030227571 cites W2097593062 @default.
• W2030227571 cites W2103980474 @default.
• W2030227571 cites W2104830962 @default.
• W2030227571 cites W2111662961 @default.
• W2030227571 cites W2112602910 @default.
• W2030227571 cites W2113327188 @default.
• W2030227571 cites W2117355416 @default.
• W2030227571 cites W2122476845 @default.
• W2030227571 cites W2122681475 @default.
• W2030227571 cites W2126767708 @default.
• W2030227571 cites W2127465345 @default.
• W2030227571 cites W2128208856 @default.
• W2030227571 cites W2128688922 @default.
• W2030227571 cites W2129360604 @default.
• W2030227571 cites W2130598119 @default.
• W2030227571 cites W2132157071 @default.
• W2030227571 cites W2137086207 @default.
• W2030227571 cites W2137797918 @default.
• W2030227571 cites W2140333474 @default.
• W2030227571 cites W2142928555 @default.
• W2030227571 cites W2143843774 @default.
• W2030227571 cites W2145899075 @default.
• W2030227571 cites W2147038864 @default.
• W2030227571 cites W2147292286 @default.
• W2030227571 cites W2155014512 @default.
• W2030227571 cites W2157900261 @default.
• W2030227571 cites W2160982674 @default.
• W2030227571 cites W2163629116 @default.
• W2030227571 cites W2166084034 @default.
• W2030227571 cites W2168385202 @default.
• W2030227571 cites W4236244375 @default.
• W2030227571 cites W4239112513 @default.
• W2030227571 doi "https://doi.org/10.1097/jto.0b013e3182745948" @default.
• W2030227571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3506112" @default.
• W2030227571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23154552" @default.
• W2030227571 hasPublicationYear "2012" @default.
• W2030227571 type Work @default.
• W2030227571 sameAs 2030227571 @default.
• W2030227571 citedByCount "547" @default.
• W2030227571 countsByYear W20302275712013 @default.
• W2030227571 countsByYear W20302275712014 @default.
• W2030227571 countsByYear W20302275712015 @default.
• W2030227571 countsByYear W20302275712016 @default.
• W2030227571 countsByYear W20302275712017 @default.
• W2030227571 countsByYear W20302275712018 @default.
• W2030227571 countsByYear W20302275712019 @default.
• W2030227571 countsByYear W20302275712020 @default.
• W2030227571 countsByYear W20302275712021 @default.
• W2030227571 countsByYear W20302275712022 @default.
• W2030227571 countsByYear W20302275712023 @default.
• W2030227571 crossrefType "journal-article" @default.
• W2030227571 hasAuthorship W2030227571A5005886886 @default.
• W2030227571 hasAuthorship W2030227571A5012323508 @default.
• W2030227571 hasAuthorship W2030227571A5031938359 @default.
• W2030227571 hasAuthorship W2030227571A5034705456 @default.
• W2030227571 hasAuthorship W2030227571A5044093871 @default.
• W2030227571 hasAuthorship W2030227571A5044715236 @default.
• W2030227571 hasAuthorship W2030227571A5052885079 @default.
• W2030227571 hasAuthorship W2030227571A5052966036 @default.
• W2030227571 hasAuthorship W2030227571A5071670695 @default.
• W2030227571 hasAuthorship W2030227571A5072767282 @default.
• W2030227571 hasAuthorship W2030227571A5082517668 @default.

• next